All News

Top news of the week from Specialty Pharmacy Times.

Sofosbuvir-based regimens for the treatment of hepatitis C were well tolerated in Asian American communities, according to a new study.

QS/1, a health care software solutions company, is partnering with Digital Pharmacist, Inc. to offer secure, HIPAA-compliant methods of patient communication through a variety of platforms.

Officials with the FDA have permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin under the skin for children and adults with diabetes.

The flu vaccine prevented 7.1 million illnesses, according to the analysis, along with 109,000 hospitalizations, and 8000 deaths, during the 2017-2018 influenza season.

Some pharmacists are not taking the time to stay hydrated and use the restroom, which can lead to serious health consequences.

A small mid-stage study demonstrated promising results for gene therapy candidate AMT-061 in patients with severe hemophilia B.

The trial evaluated margetuximab compared with trastuzumab, in combination with chemotherapy, for the treatment of HER 2-positive breast cancer.

Top news of the day across the health care landscape.

Those with hepatitis B virus have a significantly elevated risk for developing any type of age-related macular degeneration, according to a new report

Officials with the FDA have approved Novartis’ triclabendazole (Egaten) for the treatment of fascioliasis, also known as liver fluke infestation, in patients age 6 years and older.

Ryan, who was elected as the 54th Speaker of the House in 2015 and served in that role until January 2019 will speak as part of the Business Program, scheduled for Tuesday April 30.

An FDA program is seeking to facilitate better quality drug manufacturing through recognized consensus standards.

A new FDA program aims to facilitate better quality drug manufacturing through recognized consensus standards.

Amid a global measles outbreak, some teenagers are questioning their anti-vaxxer parents about not vaccinating them against many dangerous and deadly diseases.

Top news of the day across the health care landscape.

For fourth-year residency candidates across the nation, January through March is often a whirlwind of presentations, program overviews, panels, and a plethora of questions.

Phase 3 trial evaluating isatuximab in combination with standard of care met the primary endpoint of prolonging progression-free survival.

If approved, apalutamide (Erleada) plus androgen deprivation therapy would offer an additional treatment option for patients with metastatic castration-sensitive prostate cancer.

Top news of the day across the health care landscape.

Camber recently announced the FDA approval of Tolterodine Tartrate ER capsules, a generic version of Detrol LA (tolterodine, Pharmacia & Upjohn).

Pharmacy DIR fees increasingly are being misused by payers to retroactively claw back reimbursement to pharmacies for the prescription drugs that they provide to Medicare beneficiaries.

The FDA announced approval of Wixela Inhub on January 30, 2019.

An FDA Advisory Committee has recommended the agency’s approval of Janssen’s esketamine nasal spray CIII (Spravato) for adults living with treatment-resistant depression.

The generic product (Wixela Inhub, Mylan) will be offered in 3 strengths at wholesale acquisition costs that are 70% less than the brand equivalent Advair Diskus, according to Mylan.

Biologic therapy used to treat severe psoriasis found to improve coronary artery plaque burden.

Daratumumab was first approved in November 2015 as the first and only CD38-directed antibody for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to both.

The new approval allows for daratumumab (Darzalex) to be administered as a split infusion over 2 consecutive days.